Analysts See $-0.37 EPS for vTv Therapeutics Inc. (VTVT) as of May, 2

April 20, 2018 - By Andre Harris

On May, 2 is awaited vTv Therapeutics Inc. (NASDAQ:VTVT)’s earnings report, according to Faxor. Analysts expect change of 15.91 % or $0.07 from previous year’s $-0.44 earnings per share compared to current’s $-0.37 earnings per share. Analysts at Wall Street see vTv Therapeutics Inc.’s -15.91 % EPS growth compared to $-0.44 earnings per share for last quarter. VTVT reached $2.19 during the last trading session after $0.08 change.vTv Therapeutics Inc. has 1.38M shares volume, 14.11% up from normal. VTVT is downtrending and has moved 34.95% since April 20, 2017. The stock underperformed the S&P 500 by 46.50%.

vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers, develops, and sells orally administered small molecule drug candidates worldwide.The firm is worth $71.86 million. The company's drug candidate for the treatment of Alzheimer's disease comprise azeliragon , an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts, which is in Phase III clinical trials.Last it reported negative earnings. The Company’s type 2 diabetes drug candidates include TTP399, an orally administered, liver-selective glucokinase activator that has been completed Phase IIb clinical trials; and TTP273, an orally administered, non-peptide agonist that targets the glucagon-like peptide-1 receptor, which is in Phase II clinical trials.

vTv Therapeutics Inc. (NASDAQ:VTVT) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: